PRLD
Prelude Therapeutics Incorporated
stockNASDAQ
prelude therapeutics incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapies optimized to target the key driver mechanisms in cancers. it is developing prt543 that is in phase 1 clinical trials in select solid tumors and myeloid malignancies in patients who are refractory to or intolerant of established therapies; and prt811, which is in phase 1 clinical trials in solid tumors, including glioblastoma multiforme and primary central nervous system lymphomas. the company is also developing prt1419, a potent and selective inhibitor of the anti-apoptotic protein; prt2527, a potent inhibitor of cdk9 that exhibits high kinome selectivity; prt-sca2 for multiple genomically selected cancers; and prt-k4 for solid tumors. prelude therapeutics incorporated was founded in 2016 and is based in wilmington, delaware.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 3.91 | 2026-09-28 | -6.27% | -3.493 |
| 1M | 5.46 | 2026-09-04 | -32.88% | 0.992 |
| 3M | 4.99 | 2026-07-06 | -26.55% | 0.036 |
| 6M | 3.68 | 2026-04-06 | -0.41% | 0.908 |
| 1Y | 1.46 | 2025-10-06 | +151.03% | 1.914 |
| 2Y | 2.00 | 2024-10-04 | +83.25% | — |
| 5Y | 30.04 | 2021-10-05 | -87.80% | 1.512 |
Prelude Therapeutics Incorporated (NASDAQ:PRLD) stock price today is $3.67, and today's volume is 742,041. PRLD is down 3.298% today. The 30 day average volume is 516,627. PRLD market cap is $292.48M with 79.80M shares outstanding.